Calidi Biotherapeutics (CLDI) Total Liabilities (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Total Liabilities of $5.1 million for Q4 2025, down 58.26% year-over-year from $12.2 million in Q4 2024, and down 25.37% quarter-over-quarter from $6.8 million in Q3 2025.
Calidi Biotherapeutics (CLDI) Total Liabilities (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Total Liabilities history runs 5 years deep, the most recent figure standing at $5.1 million for Q4 2025.
- In Q4 2025, Total Liabilities fell 58.26% year-over-year to $5.1 million; the TTM figure through Dec 2025 stood at $5.1 million (down 58.26% YoY), while the FY2025 annual figure was $5.1 million, down 58.26% from the prior year.
- Total Liabilities for Q4 2025 stood at $5.1 million, down from $6.8 million in the prior quarter.
- The five-year high for Total Liabilities was $43.4 million in Q4 2022, with the low at $5.1 million in Q4 2025.
- The 5-year median for Total Liabilities is $12.8 million (2023), against an average of $14.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities surged 169.58% in 2024, then slumped 64.67% in 2025.
- Calidi Biotherapeutics' Total Liabilities stood at $16.5 million in 2021, then surged by 164.03% to $43.4 million in 2022, then sank by 57.97% to $18.3 million in 2023, then tumbled by 33.09% to $12.2 million in 2024, then plunged by 58.26% to $5.1 million in 2025.
- Business Quant data shows CLDI's Total Liabilities at $5.1 million in Q4 2025, $6.8 million in Q3 2025, and $7.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | 4.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.07 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | 7.28 Mn |
| Mar 31, 2025 | 7.77 Mn |
| Dec 31, 2024 | 12.21 Mn |
| Sep 30, 2024 | 16.46 Mn |
| Jun 30, 2024 | 18.18 Mn |
| Mar 31, 2024 | 21.98 Mn |
| Dec 31, 2023 | 18.25 Mn |
| Sep 30, 2023 | 19.68 Mn |
| Jun 30, 2023 | 12.77 Mn |
| Mar 31, 2023 | 8.15 Mn |
| Dec 31, 2022 | 43.44 Mn |
| Sep 30, 2022 | 10.37 Mn |
| Jun 30, 2022 | 10.08 Mn |
| Mar 31, 2022 | 14.45 Mn |
| Dec 31, 2021 | 16.45 Mn |